国际口腔医学杂志 ›› 2021, Vol. 48 ›› Issue (1): 50-57.doi: 10.7518/gjkq.2021013

• 论著 • 上一篇    下一篇

脂多糖结合蛋白在口腔鳞状细胞癌中的表达及其临床意义

黄俊文1,乔洁2,梅子1,陈茁1,李杨1,乔彬1()   

  1. 1. 郑州大学第一附属医院口腔颌面外科 郑州 450052
    2. 湖北大学生命科学学院 省部共建生物催化与酶工程国家重点实验室 武汉 430062
  • 收稿日期:2020-05-26 修回日期:2020-09-16 出版日期:2021-01-01 发布日期:2021-01-20
  • 通讯作者: 乔彬
  • 作者简介:黄俊文,硕士,Email: bettermore1993@163.com
  • 基金资助:
    河南省科技厅项目(182300410319)

Expression and clinical significance of lipopolysaccharide binding protein in oral squamous cell carcinoma

Huang Junwen1,Qiao Jie2,Mei Zi1,Chen Zhuo1,Li Yang1,Qiao Bin1()   

  1. 1. Dept. of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
    2. State Key Laboratory of Biocatalysis and Enzyme Engineering, School of Life Sciences, Hubei University, Wuhan 430062, China
  • Received:2020-05-26 Revised:2020-09-16 Online:2021-01-01 Published:2021-01-20
  • Contact: Bin Qiao
  • Supported by:
    This study was supported by Project of Department of Science and Technology of Henan Province(182300410319)

摘要:

目的 探讨脂多糖结合蛋白(LBP)在口腔鳞状细胞癌(OSCC)中的表达及其临床意义。方法 通过免疫组织化学实验分别检测LBP在48例OSCC患者的癌组织及其癌旁组织的表达情况,酶联免疫吸附试验分别检测130名OSCC患者和90名正常人血清中的LBP质量浓度,分析LBP与OSCC的临床病理特点的关系,并绘制受试者工作特征(ROC)曲线分析血清中LBP质量浓度在OSCC诊断中的价值。结果 与癌旁组织相比,LBP在OSCC组织中高表达(P<0.001),并且LBP与OSCC的肿瘤分期、淋巴结转移及临床分期有关,未发现LBP与OSCC患者的性别、年龄及病理分级有关(P>0.1)。同时,通过免疫组织化学实验发现CD204在OSCC中有类似的结果。与正常人相比,OSCC患者血清中LBP质量浓度升高(P<0.001),并与OSCC的肿瘤分期和临床分期有关(P<0.001)。ROC曲线下面积为0.876(P<0.001),LBP血清质量浓度的最佳截断值为0.733 μg·mL -1,特异性93.3%,敏感性80.0%。 结论 LBP与OSCC的发生发展有关,可能是其潜在的肿瘤标志物,提示LBP在OSCC的诊断中具有潜在的临床价值。

关键词: 脂多糖结合蛋白, 口腔鳞状细胞癌, 免疫组织化学双染, 酶联免疫吸附试验, 受试者特征工作曲线

Abstract:

Objective To investigate the expression and clinical importance of lipopolysaccharide binding protein(LBP) in oral squamous cell carcinoma (OSCC). Methods LBP expression in 48 OSCC tissues and matched adjacent normal tissues and LBP serum levels in 130 patients with OSCC and 90 normal individuals were measured by immunohistochemistry staining assay and enzyme-linked immunosorbent assay, respectively. The relationship between LBP expression and the clinicopathologic characteristics of OSCC was analysed by statistical methods. The diagnostic value of LBP serum level in OSCC was explored via receiver operating characteristic (ROC) curve. Results LBP expression was significantly upregulated in OSCC tissues, whereas little was expressed in adjacent normal tissues (P<0.001). Furthermore, LBP expression was closely associated with T-classification, node lymph metastasis and clinical stage (P<0.01) but not with the pathological grading, sex and age of patients (P>0.1). Meanwhile, it was found that CD204 had the similar results in OSCC through immunohistochemistry staining assay. The LBP serum level in patients with OSCC abnormally increased compared with that in normal individuals (P<0.001). LBP serum concentration was highly correlated to T-classification and clinical stage (P<0.001). Area under the ROC was 0.876 (P<0.001), and the optional cut-off value was 0.733 μg·mL -1 with 93.3% specificity and 80.0% sensitivity. Conclusion LBP contributes to the tumourigenesis and development of OSCC and could become a promising biomarker that might provide a useful clinical value in the early diagnosis of OSCC.

Key words: lipopolysaccharide binding protein, oral squamous cell carcinoma, immunohistochemical double-stai-ning, enzyme linked immunosorbent assay, receiver operating characteristic curve

中图分类号: 

  • R782.2

表 1

LBP的表达与OSCC患者临床病理特点的关系"

患者参数 病例数 CD204 P LBP P
性别 1.000 0.45
28 4.95(3.63~6.4) 1.32±0.54
20 4.93±0.92 1.15(0.90~1.56)
年龄/岁 0.788 0.649
<60 24 5.07±1.27 1.29±0.42
≥60 24 4.90(3.85~6.38) 1.31±0.53
临床分期 0.001 0.007
12 3.80(3.53~4.00) 1.05(0.90~1.30)
24 5.28±1.29 1.25(0.85~1.59)
12 5.65±1.13 1.75(1.20~2.20)
肿瘤分期 0.021 0.007
T1 14 3.85(3.57~4.60) 1.20(0.90~1.30)
T2 26 5.34±1.25 1.30(0.95~1.60)
T3 8 5.45±1.37 2.05(1.23~2.28)
病理分级 0.107 0.755
高分化 8 4.30±0.82 1.28±0.49
中分化 40 5.20(3.93~6.33) 1.30±0.48
淋巴结转移 0.007 0.039
N0 42 4.50(3.80~5.55) 1.24±0.45
N1-3 6 6.10(6.00~7.00) 1.70±0.50
组织来源 <0.001 <0.001
OSCC组织 48 4.90(3.93~6.08) 1.25(0.93~1.60)
癌旁组织 48 0.30(0.03~0.48) 0.05(0~0.20)

图1

LBP和CD204在OSCC组织中过表达 A和B:OSCC癌旁组织中LBP和CD204免疫组织化学双染代表性图(A为× 200,B为× 400); C和D:OSCC组织中LBP和CD204免疫组织化学双染代表性图(C为× 200,D为× 400);E:LBP和CD204在OSCC与癌旁组织中表达的量化评分。"

图2

LBP和CD204在不同的肿瘤分期以及临床分期OSCC中的表达 A、B、C:不同肿瘤分期的OSCC组织LBP和CD204免疫组织化学双染代表性图(× 200); D、E、F:不同临床分期的OSCC组织LBP和CD204免疫组织化学双染代表性图(× 200);G:不同肿瘤分期的OSCC中LBP和CD204表达水平的量化评分图;H:不同临床分期的OSCC中LBP和CD204表达水平的量化评分图。"

图3

LBP和CD204在不同的病理分级以及淋巴结转移OSCC中的表达 A、B:不同淋巴结转移状态的OSCC组织LBP和CD204免疫组织化学双染代表性图(× 200);C、D:不同病理分级的OSCC组织LBP和CD204免疫组织化学双染代表性图(× 200);E:不同淋巴结转移状态的OSCC中LBP和CD204表达水平的量化评分图;F:不同病理分级的OSCC中LBP和CD204表达水平的量化评分图。"

表2

LBP血清浓度与OSCC患者临床病理特点的关系"

患者参数 病例数 LBP/(μg·mL-1 P
性别 0.848
80 1.57(1.26~2.22)
50 1.55(1.39~1.94)
年龄/岁 0.63
<60 56 1.57±0.50
≥60 74 1.76(1.35~2.15)
临床分期 <0.001
28 1.37±0.24
48 1.63±0.60
44 1.78±0.59
10 2.73(2.11~3.11)
肿瘤分期 <0.001
T1 36 1.35(1.25~1.55)
T2 68 1.63±0.57
T3 26 2.01(1.88~2.8)
病理分级 0.221
高分化 26 1.51(1.27~1.60)
中分化 96 1.74(1.31~2.07)
低分化 8 1.78(1.35~2.24)
淋巴结转移 0.176
N0 94 1.56(1.28~1.93)
N1-3 36 1.61(1.41~2.28)

图4

The increased serum level of LBP in OSCC patients"

"

[1] Bray F, Ferlay J, Soerjomataram I , et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424.
[2] Siegel RL, Miller KD, Jemal A . Cancer statistics, 2019[J]. CA A Cancer J Clin, 2019,69(1):7-34.
[3] Grivennikov SI, Greten FR, Karin M . Immunity, inflammation, and cancer[J]. Cell, 2010,140(6):883-899.
[4] Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation[J]. Cell, 2011,144(5):646-674.
doi: 10.1016/j.cell.2011.02.013 pmid: 21376230
[5] Schumann RR, Leong SR, Flaggs GW , et al. Structure and function of lipopolysaccharide binding protein[J]. Science, 1990,249(4975):1429-1431.
[6] Zweigner J, Schumann RR, Weber JR . The role of lipopolysaccharide-binding protein in modulating the innate immune response[J]. Microbes Infect, 2006,8(3):946-952.
doi: 10.1016/j.micinf.2005.10.006 pmid: 16483818
[7] Tsukamoto H, Takeuchi S, Kubota K , et al. Lipopolysaccharide (LPS)-binding protein stimulates CD 14-dependent Toll-like receptor 4 internalization and LPS-induced TBK1-IKKϵ-IRF3 Axis activation[J]. J Biol Chem, 2018,293(26):10186-10201.
[8] Ryu JK, Kim SJ, Rah SH , et al. Reconstruction of LPS transfer cascade reveals structural determinants within LBP, CD14, and TLR4-MD2 for efficient LPS recognition and transfer[J]. Immunity, 2017,46(1):38-50.
[9] Kopp F, Kupsch S, Schromm AB . Lipopolysaccharide-binding protein is bound and internalized by host cells and colocalizes with LPS in the cytoplasm: implications for a role of LBP in intracellular LPS-signaling[J]. Biochim Biophys Acta, 2016,1863(4):660-672.
[10] Boylan KL, Andersen JD, Anderson LB , et al. Quantitative proteomic analysis by iTRAQ(R) for the iden-tification of candidate biomarkers in ovarian cancer serum[J]. Proteome Sci, 2010,8:31.
[11] Kovacs G, Peterfi L, Farkas N , et al. Expression of inflammatory lipopolysaccharide binding protein (LBP) predicts the progression of conventional renal cell carcinoma‒a short report[J]. Cell Oncol (Dordr), 2017,40(6):651-656.
[12] Peterfi L, Yusenko MV, Kovacs G . IL6 shapes an inflammatory microenvironment and triggers the development of unique types of cancer in end-stage kidney[J]. Anticancer Res, 2019,39(4):1869-1874.
[13] Wang N, Song XG, Liu LS , et al. Circulating exosomes contain protein biomarkers of metastatic non-small-cell lung cancer[J]. Cancer Sci, 2018,109(5):1701-1709.
[14] Kouketsu A, Sato I, Oikawa M , et al. Regulatory T cells and M2-polarized tumour-associated macropha-ges are associated with the oncogenesis and progression of oral squamous cell carcinoma[J]. Int J Oral Maxillofac Surg, 2019,48(10):1279-1288.
[15] Yamagata Y, Tomioka H, Sakamoto K , et al. CD163-positive macrophages within the tumor stroma are associated with lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma[J]. J O-ral Maxillofac Surg, 2017,75(10):2144-2153.
[16] ASMRHaque, Moriyama M, Kubota K, et al. CD206 + tumor-associated macrophages promote proliferation and invasion in oral squamous cell carcinoma via EGF production [J]. Sci Rep, 2019,9(1):14611.
[17] Wang B, Liu H, Dong XL , et al. High CD204 + tumor-infiltrating macrophage density predicts a poor prognosis in patients with urothelial cell carcinoma of the bladder [J]. Oncotarget, 2015,6(24):20204-20214.
[18] Kawachi A, Yoshida H, Kitano S , et al. Tumor-associated CD204 + M2 macrophages are unfavorable pro-gnostic indicators in uterine cervical adenocarcinoma [J]. Cancer Sci, 2018,109(3):863-870.
[19] Wang YP, Chen C, Hua QQ , et al. Downregulation of leucine‑rich‑α‑2‑glycoprotein 1 expression is associated with the tumorigenesis of head and neck squamous cell carcinoma[J]. Oncol Rep, 2017,37(3):1503-1510.
[20] Chen R, Luo FK, Wang YL , et al. LBP and CD14 polymorphisms correlate with increased colorectal carcinoma risk in Han Chinese[J]. World J Gastroenterol, 2011,17(18):2326-2331.
[21] Chang CM, Chia VM, Gunter MJ , et al. Innate immunity gene polymorphisms and the risk of colorectal neoplasia[J]. Carcinogenesis, 2013,34(11):2512-2520.
[22] Cai QY, Jiang JH, Jin RM , et al. The clinical significance of lipopolysaccharide binding protein in hepatocellular carcinoma[J]. Oncol Lett, 2020,19(1):159-166.
[23] Kubota K, Moriyama M, Furukawa S , et al. CD163 + CD204 + tumor-associated macrophages contribute to T cell regulation via interleukin-10 and PD-L1 production in oral squamous cell carcinoma [J]. Sci Rep, 2017,7(1):1755.
[24] Kurago ZB, Lam-ubol A, Stetsenko A, et al. Lipopolysaccharide-squamous cell carcinoma-monocyte interactions induce cancer-supporting factors leading to rapid STAT3 activation[J].Head Neck Pathol, 2008,2(1):1-12.
[25] Utispan K, Pugdee K, Koontongkaew S . Porphyromonas gingivalis lipopolysaccharide-induced ma-crophages modulate proliferation and invasion of head and neck cancer cell lines[J]. Biomed Pharmacother, 2018,101:988-995.
[1] 何宇晴,但红霞,陈谦明. 光动力疗法在口腔黏膜癌变防治中的应用[J]. 国际口腔医学杂志, 2020, 47(6): 669-676.
[2] 郝福,宁毅,孙睿,郑晓旭. 口腔鳞状细胞癌中转化因子2β的表达及潜在的临床意义[J]. 国际口腔医学杂志, 2020, 47(2): 159-165.
[3] 薛伶俐,李雅冬. 经首次根治性手术治疗口腔鳞状细胞癌患者的生存相关影响因素分析[J]. 国际口腔医学杂志, 2020, 47(2): 166-174.
[4] 董云梅,陶艳,周瑜. 口腔黏膜癌变过程中血清生化标志物的研究进展[J]. 国际口腔医学杂志, 2020, 47(1): 43-50.
[5] 陈宏丽,杨敬,尹刚,李皓缘,乔燕. 锌指蛋白32在口腔鳞状细胞癌中的表达意义及对口腔鳞状细胞癌干细胞的影响[J]. 国际口腔医学杂志, 2019, 46(6): 631-639.
[6] 闫冰,骆献阳,谭迎赟,关丽梅,薛丽丽. 血清表面增强拉曼光谱应用于口腔鳞状细胞癌患者临床分期的研究[J]. 国际口腔医学杂志, 2019, 46(3): 277-281.
[7] 李群,关为群,张杨安,黄志超. 骨膜蛋白和p53在口腔白斑及鳞状细胞癌组织中的表达及意义[J]. 国际口腔医学杂志, 2019, 46(1): 5-11.
[8] 李媛媛,程斌,王韵. 长链非编码RNA lnc-p26090对口腔鳞状细胞癌细胞糖酵解及增殖的影响[J]. 国际口腔医学杂志, 2018, 45(6): 628-634.
[9] 王伊婷,何永文. 口腔鳞状细胞癌相关长链非编码RNA调控肿瘤细胞上皮-间充质转化的研究进展[J]. 国际口腔医学杂志, 2018, 45(6): 635-639.
[10] 方川,李雅冬. 微小RNA在口腔鳞状细胞癌中的研究进展[J]. 国际口腔医学杂志, 2018, 45(6): 646-651.
[11] 余芯乐, 郑军, 徐江, 曾妍. 口腔鳞状细胞癌患者唾液和血清中N-α-乙酰基转移酶10的水平及其临床意义[J]. 国际口腔医学杂志, 2018, 45(4): 391-395.
[12] 王琨,葛奕辰,崔博淼,苟雅萍,孙崇奎,龙敏,肖丽,英李燕. 端粒酶卡侯体蛋白1干扰慢病毒对口腔鳞状细胞癌细胞裸鼠致瘤作用的研究[J]. 国际口腔医学杂志, 2017, 44(1): 32-36.
[13] 刘盼1,多力昆?吾甫尔1,蔡志刚2,孙坚3. 维吾尔族口腔鳞状细胞癌患者中血清鳞状细胞癌抗原的表达研究[J]. 国际口腔医学杂志, 2016, 43(6): 645-650.
[14] 涂敏松1 李逸松2 代晓明2. DNA甲基化与口腔鳞状细胞癌的相关性研究进展[J]. 国际口腔医学杂志, 2016, 43(1): 79-.
[15] 李蓝江1 许冰莹1 杨春艳2 赵川3 田心2. 基质金属蛋白酶1、3和9基因多态性与云南汉族人群口腔鳞状细胞癌发病风险的相关性研究[J]. 国际口腔医学杂志, 2015, 42(6): 631-634.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 逄键梁. 两例外胚层发育不良儿童骨内植入种植体后牙槽骨生长情况[J]. 国际口腔医学杂志, 1999, 26(05): .
[2] 张婷,莫安春. 暂时冠桥修复材料的研究进展[J]. 国际口腔医学杂志, 2008, 35(S1): .
[3] 骆琳,王航. 口腔环境对牙科树脂复合材料摩擦学的影响[J]. 国际口腔医学杂志, 2008, 35(S1): .
[4] 叶年嵩 王晟综述 赖文莉审校. 非综合征性先天缺牙相关基因的研究进展[J]. 国际口腔医学杂志, 2011, 38(4): 416 -418 .
[5] 陈哲1 王璟2综述 王虎3审校. 音乐疗法在口腔领域中的应用[J]. 国际口腔医学杂志, 2011, 38(6): 734 -737 .
[6] 赵熠1 蔡育2综述 王贻宁1审校. 破骨细胞前体细胞的研究进展[J]. 国际口腔医学杂志, 2011, 38(6): 670 -673 .
[7] 徐玮综述 赵克, 张新平审校. 牙科镍钛形状记忆合金的表面改性[J]. 国际口腔医学杂志, 2010, 37(02): 221 -221~224 .
[8] 吴卫锋 雷丹 姜苏 高雳. 安止痛牙龈膏对牙龈卟啉单胞菌和伴放线嗜血菌及具核梭杆菌的抑菌作用[J]. 国际口腔医学杂志, 2011, 38(2): 138 -140 .
[9] 陈意 陶人川 林雪芳 刘贞敏 雍翔智 李润英. 人中性粒细胞防御素1~3的日节律性分泌[J]. 国际口腔医学杂志, 2013, 40(4): 429 -431 .
[10] 高宇1 吴占敖1 冯卫忠1 丁妍1 张德云2 姜涛1. 不同浓度硅酸钠溶液液相沉积处理对钛瓷结合强度的影响[J]. 国际口腔医学杂志, 2013, 40(4): 440 -443 .